Error loading player: No playable sources found
AM24-MN-23-O
AM24-MN-23-O: Oral Abstracts - Pathogen Reduction (Enduring)
Date
October 23, 2024
Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP)
$30
Standard Price
Members save $5
This product is also available as part of the following products:
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…
Oral abstracts about pathogen reduction.
Learning Objectives
- Describe the relationship between pathogen reduced RBCs and HLA allommunization risk.
- Understand if PRT-PLTs are non-inferior to PAS-PLTs in cardiac surgery patients with respect to correction of MA.
- Define clinical outcomes with respect to blood component utilization and chest tube drainage between PRT-PLTs and PAS-PLTs.
- Outline the benefits of using Pathogen Reduced Cryoprecipitated Fibrinogen Complex, Intercept Fibrinogen Complex in a transfusion medicine service.
- Describe the incidence of treatment emergent antibodies with specificity for PRRBCs.
Speakers
Magali J. Fontaine, MD, PhD
Professor of Pathology and Medicine, University of Maryland School of Medicine
Richard Benjamin, MD
Cerus Corporation, Concord, CA, USA
Melissa Cushing, MD
Executive Vice Chair, Weill Cornell Medicine
Moderators
Edward Lee, MD, PhD
Yale School of Medicine
Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA
Related Products
AM24-TU-09-O: Duffy (ACKR1): Antibodies, Chemokines and Potential Therapeutic Targets-Not Just for Transfusion Anymore (Enduring)
Outside of Rh, the Duffy (Fy) blood group is one of the most important non-ABO blood groups worldwide…
AM24-TU-15-O: Oral Abstracts - Genomics (Enduring)
Oral abstracts about Genomics…
AM24-MN-28-O: Choose Your Own Adventure: Exploring the Depths of Serology and Peaks of Genomics (Enduring)
What do you do when you discover an unexpected antigen typing? Do you investigate history, rule out sample switch, opt for a different serologic technique, or refer for DNA testing? What about when you encounter an antibody of unidentified specificity? Which test do you perform next, and once the a…
AM24-TU-12-O: Lord of the Antibodies (Enduring)
This is a first in a proposed series where we will look at antibodies to red cell antigens that are more prevalent in different parts of the world. Our journey starts in the Shire (USA) as we encounter antibodies relevant to the area we work in…
